SNY News and Press, Sanofi From 05/08/24

2024-05-08 12:01:57 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investible candidates that may b...

2024-05-08 10:46:32 ET More on Pfizer Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet Boy given Pfizer experimental Duchenne muscular dystrophy therapy dies P...

2024-05-08 10:33:00 ET Sanofi (NASDAQ: SNY) believes it has a potential blockbuster in its innovative new cancer-fighting drug. If the company is right, investing now could pay off handsomely in the future, for those with patience. Sanofi's rilzabrutinib performed well in its ph...

2024-05-08 09:00:20 ET Sanofi (SNY) declaring a stock dividend of $1.47802 per share on Ex-Date : May 09, 2024. Shareholders on record as of May 10, 2024 are eligible for the dividend. The payment date is scheduled for June 06, 2024, and the declaration was officially made on March ...

2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte

2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

2024-05-02 07:15:00 ET The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several reasons. Many are highly innovative corporations that develop break...

2024-05-01 14:27:40 ET Summary Sanofi acquired Inbrx to add lung disorders to its treatment portfolio, with an estimated sales peak of €600 million by 2032. The company settled 4,000 lawsuits related to Zantac, which is not expected to impact its balance sheet significantly...

2024-04-30 11:30:18 ET Summary Sanofi beat Q1 earnings estimates with revenue at $11.36 billion and EPS at 97 cents, driven largely by Dupixent. Key drugs like Nexviazyme and Altuviiio showed strong performance, with the former doubling its revenue. Despite a high profitabilit...

2024-04-28 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...